Jason Lewis

Jason G. Lewis, Ph.D. joined Lycia Therapeutics as Vice President and Head of Chemistry in September 2021. Prior to that, he has served as Vice President of Medicinal Chemistry at Ardelyx where he built a broad chemistry platform in GI selective therapeutics. Jason’s passion is applying innovative chemistry and data-driven design to the discovery of differentiated therapeutics. Since beginning his pharma carrier in 1992 Jason has held positions with Gilead, Vicuron and Threshold Pharmaceuticals and worked in collaboration with KKC, Astra Zeneca, Sanofi, Pfizer and Novartis. He graduated from Stanford with a B.S. in Biology and earned his Ph.D. in Chemistry at University of California, Berkeley under Prof. Paul A. Bartlett. Jason’s numerous patents and publications span the areas of Organic Synthesis, Antimicrobials, Targeted Chemotherapy, Therapeutic Oligonucleotides, Drug Delivery, and novel ligands for GPCR and SLC transporter targets.